GenBank Accession No. | Transcript | ΔFold over Sham | % Difference | ||
---|---|---|---|---|---|
Vehicle | Pioglitazone | ||||
6 h after SCI | |||||
NM_031168 | IL-6 | 14.4 ± 2.7 | 3.3 ± 0.8 | –82.8* | |
M98820 | IL-1β | 7.4 ± 1.2 | 1.8 ± 0.2 | –87.5* | |
BC008626 | ICAM-1 | 4.1 ± 1.0 | 1.5 ± 0.2 | –83.9* | |
AF065933 | Scya2 (MCP-1) | 6.7 ± 1.3 | 2.4 ± 0.5 | –75.4* | |
NM_012551 | Egr-1 | 3.4 ± 1.1 | 1.8 ± 0.4 | –66.7* | |
24 h after SCI | |||||
NM_031168 | IL-6 | 83.9 ± 12.2 | 25.3 ± 2.8 | –70.7* | |
M98820 | IL-1β | 38.2 ± 4.9 | 15.6 ± 2.2 | –60.8* | |
BC008626 | ICAM-1 | 17.1 ± 2.7 | 4.2 ± 0.7 | –80.1* | |
AF065933 | Scya2 (MCP-1) | 38.6 ± 6.2 | 21.5 ± 3.1 | –45.5* | |
NM_012551 | Egr-1 | 20.8 ± 3.5 | 12.2 ± 0.9 | –43.3* | |
M34253 | IRF-1 | 3.1 ± 0.5 | 1.9 ± 0.3 | –57.1* | |
NM_030612 | NF-κB1 | 6.2 ± 1.3 | 3.6 ± 0.8 | –50.0* | |
U03561 | HSP27 | 16.9 ± 3.3 | 24.4 ± 2.1 | +47.2* | |
AW763765 | HSP70 | 4.2 ± 0.8 | 8.7 ± 1.1 | +140.6* | |
NM_010442 | HSP32/HO-1 | 13.4 ± 2.3 | 21.7 ± 2.1 | +66.9* | |
NM_017165 | GPx | 2.2 ± 0.2 | 3.3 ± 0.5 | +91.6* | |
BC081853 | Catalase | 2.9 ± 0.8 | 5.8 ± 1.2 | +152.6* |
↵* P < 0.05 when the pioglitazone/SCI group was compared with the vehicle/SCI group (Student's t test)